Fresh headlines from around the world. Gaming, politics, technology and everything in between.
Amplia Therapeutics has advanced its cancer drug narmafotinib across four trials, with data suggesting it may work independently of common tumour-causing KRAS gene mutations.
Source: National Cancer Institute - Related MedlinePlus Pages: Pancreatic Cancer
Allnira republishes accessible articles under owner-declared permissions, with original authors, publishers and image credits. Automatic cloud imports run hourly; open pages check for updates every 15 seconds. Publication delays depend on each feed.